Treatment of Advanced Ovarian and Fallopian Tube Cancer Using Integrated Genomic Diagnostics via Ultrasound-Guided Fine-Needle Biopsy

Treatment of Advanced Ovarian and Fallopian Tube Cancer Using Integrated Genomic Diagnostics via Ultrasound-Guided Fine-Needle Biopsy - Treatment of Advanced Ovarian and Fallopian Tube Cancer Using Integrated Genomic Diagnostics via Ultrasound-Guided Fine-Needle Biopsy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061125

Enrollment

Registered

2026-04-06

Start date

2023-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced ovarian and fallopian tube cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients currently receiving outpatient care at Kagoshima University Hospital who are 20 years of age or older and capable of providing informed consent, and who are suspected of having ovarian or fallopian tube cancer

Exclusion criteria

Exclusion criteria: Other than the above

Design outcomes

Primary

Measure	Time frame
Evaluation of the feasibility of conducting an integrated analysis using histological diagnosis via ultrasound-guided biopsy and genomic panel testing in the initial treatment of advanced ovarian and fallopian tube cancer	—

Countries

Japan

Contacts

Public ContactShintaro Yanazume

Kagoshima University Hospital Department of Obstetrics and Gynecology

s-yana@m3.kufm.kagoshima-u.ac.jp0992755423

Outcome results